IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2757-2766

  Hosoyama, Tohru ^a   Aslam, Mohammed Imran ^a   Abraham, Jinu ^a,e   Prajapati, Suresh I ^a   Nishijo, Koichi ^a   Michalek, Joel E ^a,b   Zarzabal, Lee Ann ^a   Nelon, Laura D ^a   Guttridge, Denis C ^c   Rubin, Brian P ^d   Keller, Charles ^a,b,e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MYOD PROTEIN; MYOGENIN; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT6 PROTEIN; TRANSCRIPTION FACTOR PAX7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CELL DEDIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MITOGENESIS; MOUSE; MUSCLE DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CELL DEDIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENES, P53; HUMANS; MICE; MICE, TRANSGENIC; MITOGENS; MUSCLE NEOPLASMS; MYOGENIC REGULATORY FACTORS; NEOPLASM METASTASIS; PAIRED BOX TRANSCRIPTION FACTORS; RECEPTORS, INTERLEUKIN-4; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION;

EID: 79955485955     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3445     Document Type: Article

References (39)

1. Jankowski K, Kucia M, Wysoczynski M, Reca R, Zhao D, Trzyna E, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003;63:7926-35. (Pubitemid 37466729)
2. Qualman SJ, Coffin CM, Newton WA, Hojo H, Triche TJ, Parham DM, et al. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol 1998;1:550-61. (Pubitemid 128542175)
3. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004;18:2614-26. (Pubitemid 39453101)
4. Horsley V, Jansen KM, Mills ST, Pavlath GK. IL-4 acts as a myoblast recruitment factor during mammalian muscle growth. Cell 2003;113: 483-94. (Pubitemid 36588751)
5. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16:91-102.
6. Nanni P, Nicoletti G, Palladini A, Astolfi A, Rinella P, Croci S, et al. Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. Mol Cancer Ther 2009;8: 754-61.
7. Keller C, Hansen MS, Coffin CM, Capecchi MR. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 2004;18:2608-13. (Pubitemid 39453100)
8. Nishijo K, Hosoyama T, Bjornson CR, Schaffer BS, Prajapati SI, Bahadur AN, et al. Biomarker system for studying muscle, stem cells, and cancer in vivo. Faseb J 2009;23:2681-90.
9. Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, Infante AJ, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008;27:6550-60.
10. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999;17:701-38. (Pubitemid 29241138)
11. Chatila TA. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends Mol Med 2004;10:493-9. (Pubitemid 39303622)
12. Letzelter F, Wang Y, Sebald W. The interleukin-4 site-2 epitope determining binding of the common receptor gamma chain. Eur J Biochem 1998;257:11-20. (Pubitemid 28462575)
13. Miloux B, Laurent P, Bonnin O, Lupker J, Caput D, Vita N, et al. Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex. FEBS Lett 1997;401:163-6. (Pubitemid 27056108)
14. Murata T, Taguchi J, Puri RK. Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. Blood 1998;91:3884-91. (Pubitemid 28225757)
15. Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995;270:8797-804.
16. Obiri NI, Leland P, Murata T, Debinski W, Puri RK. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol 1997;158:756-64. (Pubitemid 127492652)
17. Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 2009;69:8678-85.
18. Oustanina S, Hause G, Braun T. Pax7 directs postnatal renewal and propagation of myogenic satellite cells but not their specification. Embo J 2004;23:3430-9. (Pubitemid 39209166)
19. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is required for the specification of myogenic satellite cells. Cell 2000;102:777-86.
20. Berkes CA, Tapscott SJ. MyoD and the transcriptional control of myogenesis. Semin Cell Dev Biol 2005;16:585-95. (Pubitemid 41247882)
21. Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 1993;259:1450-3. (Pubitemid 23101380)
22. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-102. (Pubitemid 32567502)
23. Wills-Karp M, Finkelman FD. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal 2008;1:pe55.
24. Zammit PS, Relaix F, Nagata Y, Ruiz AP, Collins CA, Partridge TA, et al. Pax7 and myogenic progression in skeletal muscle satellite cells. J Cell Sci 2006;119:1824-32. (Pubitemid 43811008)
25. Sabourin LA, Girgis-Gabardo A, Seale P, Asakura A, Rudnicki MA. Reduced differentiation potential of primary MyoD-/- myogenic cells derived from adult skeletal muscle. J Cell Biol 1999;144:631-43. (Pubitemid 29234543)
26. Keegan AD, Johnston JA, Tortolani PJ, McReynolds LJ, Kinzer C, O'Shea JJ, et al. Similarities and differences in signal transduction by interleukin 4 and interleukin 13: analysis of Janus kinase activation. Proc Natl Acad Sci U S A 1995;92:7681-5.
27. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003;300: 1527-8. (Pubitemid 36686713)
28. Pernis A, Witthuhn B, Keegan AD, Nelms K, Garfein E, Ihle JN, et al. Interleukin 4 signals through two related pathways. Proc Natl Acad Sci U S A 1995;92:7971-5.
29. Ostrand-Rosenberg S, Grusby MJ, Clements VK. Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J Immunol 2000;165:6015-9.
30. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1: 515-20.
31. Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, Carathers M , et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005;8:421-32. (Pubitemid 41579836)
32. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010;24:241-55.
33. Shapiro DN, Jones BG, Shapiro LH, Dias P, Houghton PJ. Antisensemediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 1994;94:1235-42. (Pubitemid 24286468)
34. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 2005;16;530-40.
35. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65:3868-76. (Pubitemid 40616368)
36. Soon L, Flechner L, Gutkind JS, Wang LH, Baserga R, Pierce JH, et al. Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of insulin receptor substrate expression. Mol Cell Biol 1999;19:3816-28. (Pubitemid 29193841)
37. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al. A randomized, controlled, phase 2 study of AMG 317, an IL- 4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181:788-96.
38. Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002;130:93-100.
39. Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, et al. Convection-enhanced delivery of cintredekin besudotox (Interleukin-13- Pe38qqr) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery 2007;61:1031-338.